Adial Pharmaceuticals, Inc.
ADILNASDAQHealthcare● Active
$2.21
+$0.00(+0.00%)
Market Cap$2120813
P/E Ratio—
52W High$19
52W Low$1.31
Adial Pharmaceuticals, Inc. (ADIL) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ADIL · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 8, 2026EPS Actual
-$1.48
Est. -$2.73 · +45.8%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 8, 2026
After Market Close
▲ Beat EPS🔥 7-Quarter EPS Beat Streak
ADIL reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.02
Rev. $0.33B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.02
Rev. Est.$0.33B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$1.06 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 8, 2026 | -$2.73 | -$1.48 | +45.8% | — | — | — |
| ▲ Q1 FY2026 | Mar 10, 2026 | -$2.10 | -$1.81 | +13.8% | — | — | — |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$2.25 | -$2.00 | +11.1% | — | — | — |
| ▲ Q3 FY2025 | Aug 13, 2025 | -$0.22 | -$0.18 | +18.2% | — | — | — |
| ▲ Q2 FY2025 | May 14, 2025 | -$0.50 | -$0.34 | +32.0% | — | — | — |
| ▲ Q1 FY2025 | Mar 4, 2025 | -$0.38 | -$0.15 | +60.5% | — | — | — |
| ▲ Q4 FY2024 | Nov 13, 2024 | -$0.50 | -$0.38 | +24.0% | — | — | — |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$1.06
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 8, 2026Beat
EPS Actual
-$1.48
EPS Est.
-$2.73
EPS Surpr.
+45.8%
Revenue
—
Q1 FY2026
Mar 10, 2026Beat
EPS Actual
-$1.81
EPS Est.
-$2.10
EPS Surpr.
+13.8%
Revenue
—
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$2.00
EPS Est.
-$2.25
EPS Surpr.
+11.1%
Revenue
—
Q3 FY2025
Aug 13, 2025Beat
EPS Actual
-$0.18
EPS Est.
-$0.22
EPS Surpr.
+18.2%
Revenue
—
Q2 FY2025
May 14, 2025Beat
EPS Actual
-$0.34
EPS Est.
-$0.50
EPS Surpr.
+32.0%
Revenue
—
Q1 FY2025
Mar 4, 2025Beat
EPS Actual
-$0.15
EPS Est.
-$0.38
EPS Surpr.
+60.5%
Revenue
—
Q4 FY2024
Nov 13, 2024Beat
EPS Actual
-$0.38
EPS Est.
-$0.50
EPS Surpr.
+24.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.52 | $-0.52 | $-0.52 | 1 |
| Q3 FY2027 | $-0.50 | $-0.50 | $-0.50 | 1 |
| Q2 FY2027 | $-0.85 | $-0.85 | $-0.85 | 1 |
| Q1 FY2027 | $-0.82 | $-0.82 | $-0.82 | 1 |
| Q4 FY2026 | $-1.07 | $-1.07 | $-1.07 | 1 |
| Q3 FY2026 | $-1.16 | $-1.16 | $-1.16 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 8, 2026 | +45.8% | $1.42 | $1.43 | +0.70% |
| ▲ Q1 FY2026 | Mar 10, 2026 | +13.8% | $1.72 | $1.83 | +6.40% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +11.1% | $8.25 | $8.00 | -3.03% |
| ▲ Q3 FY2025 | Aug 13, 2025 | +18.2% | $10.00 | $10.00 | +0.00% |
| ▲ Q2 FY2025 | May 14, 2025 | +32.0% | $15.75 | $16.25 | +3.17% |
| ▲ Q1 FY2025 | Mar 4, 2025 | +60.5% | $18.25 | $18.75 | +2.74% |
| ▲ Q4 FY2024 | Nov 13, 2024 | +24.0% | $25.50 | $24.75 | -2.94% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -51.3% | $24.25 | $24.25 | +0.00% |
Q2 FY2026+0.70%
Report Date
May 8, 2026
EPS Beat/Miss
+45.8%
Price Before
$1.42
Price After
$1.43
Q1 FY2026+6.40%
Report Date
Mar 10, 2026
EPS Beat/Miss
+13.8%
Price Before
$1.72
Price After
$1.83
Q4 FY2025-3.03%
Report Date
Nov 13, 2025
EPS Beat/Miss
+11.1%
Price Before
$8.25
Price After
$8.00
Q3 FY2025+0.00%
Report Date
Aug 13, 2025
EPS Beat/Miss
+18.2%
Price Before
$10.00
Price After
$10.00
Q2 FY2025+3.17%
Report Date
May 14, 2025
EPS Beat/Miss
+32.0%
Price Before
$15.75
Price After
$16.25
Q1 FY2025+2.74%
Report Date
Mar 4, 2025
EPS Beat/Miss
+60.5%
Price Before
$18.25
Price After
$18.75
Q4 FY2024-2.94%
Report Date
Nov 13, 2024
EPS Beat/Miss
+24.0%
Price Before
$25.50
Price After
$24.75
Q3 FY2024+0.00%
Report Date
Aug 13, 2024
EPS Beat/Miss
-51.3%
Price Before
$24.25
Price After
$24.25
Avg Beat Reaction+1.01%
Avg Miss Reaction+0.00%
Beat Rate7 / 8 quarters
Largest Move+6.40% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ADIL ends December
Adial Pharmaceuticals, Inc. (ADIL) most recently reported earnings on May 8, 2026 for Q2 FY2026, posting EPS of $-1.48 — beating the analyst consensus of $-2.73 by +45.8%. ADIL has beaten EPS estimates for 7 consecutive quarters. The next ADIL earnings date is expected around September 1, 2026.
Each quarter, investors track ADIL earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ADIL revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ADIL's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ADIL earnings · 5 questionsAdial Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. ADIL typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ADIL historically reports after market close (AMC).
ADIL earnings datewhen is ADIL earningsADIL next earnings datewhen does ADIL report earningsADIL earnings calendar
▸ Source: FMP · Adial Pharmaceuticals, Inc. SEC filings · US GAAP · Adial Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026